Background/Aims: Breast cancer (BC) starts as a local disease, but it can metastasize to the lymph nodes and distant organs. However, the metastatic process is still poorly understood. The mRNA microarray datasets GSE26910 and GSE33447 show that CXCL10 is up-regulated in BC, and the microRNA microarray dataset GSE38167 and a network meta-analysis of microRNA expression profile studies in human BC suggest that microRNA-34a (miR-34a) is downregulated in BC. CXCL10 was predicted as a target of miR-34a by microRNA.org. In this study, we uncovered a CXCL10-independent mechanism by which miR-34a exerts its antimetastatic activity in BC. Methods: To investigate the clinical significance of miR-34a in BC, we collected cancer tissues and paracancerous tissues from 258 patients with BC. In addition, a series of inhibitors, mimics, and siRNAs was introduced into MCF-7 and T47D cells to validate the regulatory mechanisms by which miR-34a regulates CXCL10. Next, to better understand the pivotal role of TLR signaling pathway inhibition in MCF-7 and T47D cells, we blocked the TLR signaling pathway using OxPAPC, an antagonist of TLR signaling. Results: Among BC patients, miR-34a was down-regulated, CXCL10 was up-regulated, and the TLR signaling pathway was activated. Determination of luciferase activity revealed that CXCL10 was a target of miR-34a. Through gain-and loss-of-function studies, miR-34a was demonstrated to negatively regulate CXCL10; inhibit activation of the TLR signaling pathway; significantly suppress in vitro cell proliferation, migration, and invasion; and induce apoptosis. Conclusion: Our findings suggest that functional loss or suppression of the tumor suppressor CXCL10 due to induction of miR34a leads to inhibition of the TLR signaling pathway during breast tumorigenesis, providing a novel target for the molecular treatment of breast malignancies.
Introduction
Breast cancer encompasses a class of heterogeneous malignant diseases, including many distinct entities with particular pathological and clinical features, and its prognosis and treatment are significantly affected by clinicopathological factors such as tumor size, tumor grade and progesterone receptor expression [1] . Owing to the approximately 1.7 million cases and 521, 900 deaths in 2012, breast cancer is the most commonly diagnosed cancer and the main cause of cancer-related death among women worldwide [2] . Based on gene expression subtypes, breast cancer can be sorted into luminal A and B, Her-2-enriched and basal-like [3] . Additionally, triple-negative breast cancer forms a special subgroup accounting for 10~25% of all breast cancer cases [4] . Underlying risk factors for breast cancer include being overweight, alcohol consumption, physical inactivity, nulliparous, recent use of oral contraceptives, and a long menstrual history [2] . Although neoadjuvant and systemic chemotherapy has been widely used to treat breast cancer, successful molecular-targeted therapies of any type are currently unavailable [5] . Recent studies have started to focus on the roles of miR in breast cancer development and progression [6, 7] .
As a class of small, 18~24-long non-coding RNA molecules, microRNAs (miRs) control gene expression via suppression of mRNA stability and translation [8] . Situated on chromosome 1p36. 23 , an area closely related to cancer, miR-34a is one of the best and first-studied miRs associated with carcinogenesis, and it consistently exhibits a high expression level in normal tissues [9] . miR-34a has been reported to be a novel tumor suppressor in glioma cells [10] . Furthermore, miR-34a expression has been shown to be markedly decreased in patients with breast cancer [11] . C-X-C motif ligand 10 (CXCL10), which is also known as 10 kDa IP-10, is a member of the CXC subfamily of chemokines that includes the ELR + CXC and ELR − chemokines and exerts angiostatic functions by binding to C-X-C motif receptor 3 [12] . CXC family chemokines have been validated to be overexpressed in many diseases, such as esophageal cancer and collagen-induced arthritis [13, 14] . One previous study has shown that miR decreases CXCR4 expression and blocks the migration and invasion of breast cancer cells [15] . Although non-ELR CXC chemokines such as CXCL10 can suppress angiogenesis and influence cancer regression, the mechanism by which their production is enhanced or sustained remains unclear [16] . Toll-like receptors (TLRs) are a group of pattern-recognition receptors, and the TLR system can be activated by CXCL10, with a significant effect on inflammatory and infectious diseases [17] . MiRs have been reported to function as new regulators involved in the regulation of the TLR signaling pathway [18] . Based on these findings, we speculate that miR-34a may have a role in the proliferation, invasion, migration and apoptosis of breast cancer cells by targeting CXCL10 through the TLR signaling pathway.
Materials and Methods

Gene Expression Omnibus (GEO) dataset analysis
Gene expression profiles (GSE26910, GSE33447, GSE5764, and GSE38167) related to breast cancer and probe annotation files were downloaded from the GEO database (http://www.ncbi.nlm.nih.gov/geo) and were generated on the Human Genome U133 Plus 2.0 Array, Agilent-028004 SurePrint G3 Human GE 8x60K Microarray, Human Genome U133 Plus 2.0 Array and Agilent-029297 Human miRNA Microarray, respectively (Affymetrix Inc., Santa Clara, CA, USA). Microarray data analysis was processed with background calibration and normalization using Affy installation package from R software [19] . The gene expression profiles were then non-specifically filtered using a linear model-empirical Bayes (EB) approach (Limma installation package) combined with the t test, and differentially expressed genes (DEGs) were screened out [20] . According to the WebGestalt database (http://www.webgestalt.org), gene ontology (GO) enrichment analysis was performed on these DEGs. GO enrichment analysis included cellular component, molecular function and biological process [21] . Based on the Kyoto Encyclopedia of Genes and Genomes (KEGG) database (http://www.genome.ad.jp/kegg/), pathway enrichment analysis was conducted using the
Hematoxylin and eosin (HE) staining
The collected breast cancer and normal breast tissue samples were fixed in 10% formaldehyde, embedded in paraffin and cut into 4-μm serial sections. Paraffin sections were dewaxed in xylene for 15 min; rehydrated in a gradient of 100%, 95%, 75% and 50% alcohol for 5 min each; and soaked in distilled water for 5 min. Hematoxylin (ZSGB-BIO, Beijing, China) was adopted to dye sections for 10 min, and sections were washed in tap water for 3 min. The sections were then subjected to 1% ethyl alcohol with hydrochloric acid for 10 s, ammonia to produce the blue color for 10 s, and tap water again to remove the dye solution for 2 min. Then, 0.5% eosin (ZSGB-Bio, Beijing, China) was used to re-dye the sections for 2 min, and running water was used to wash them for 10 s. Sections were dehydrated with a gradient of 70%, 80%, 95% and 100% alcohol for 2 min each, cleared with xylene and mounted with neutral balsam. A light microscope (BX-51, Olympus, Tokyo, Japan) was applied to observe the results.
Immunohistochemistry
Paraffin sections were baked in an oven at 60°C for 1 h, dewaxed with normal xylene, hydrated in an ethanol gradient, soaked in 3% hydrogen peroxide at room temperature for 10 min to eliminate the activity of endogenous peroxidase and then washed with phosphate-buffered saline (PBS). After antigen retrieval, sections were blocked with 10% goat serum for 15 min. The mouse anti-CXCL10 primary antibody (1:50, ab8098, Abcam Inc., Cambridge, MA, USA) was applied at 4°C overnight, followed by three washes with PBS. The sections were then incubated with biotin-labeled goat anti-mouse immunoglobulin G (IgG) secondary antibody (1:500, ab6789, Abcam Inc., Cambridge, MA, USA) at 37°C for 10 min and washed with PBS. Diaminobenzidine (DAB) (ZSGB-Bio, Beijing, China) was used for development for 3 to 10 min, and the sections were re-dyed with hematoxylin for 1 min, washed with running water, dehydrated and dried in a gradient of alcohol for 5 min each, cleared with xylene for 10 min and then mounted with neutral balsam.
PBS was used to replace the primary antibody as the negative control (NC). The final result was observed by two people independently. Five fields were selected randomly under a light microscope. Cells with yellow particles inside were viewed as positive cells, and the percentages of these cells among all cells were used to calculate the staining result for CXCL10: a percentage of positive cells > 10% was recorded as positive expression (+), and a percentage of positive cells < 10% was recorded as negative expression (-).
Quantitative real-time polymerase chain reaction (qRT-PCR)
Total RNA was extracted from samples using a TRIzol (Invitrogen, Carlsbad, CA, USA) one-step process. The purity and concentration of the RNA were detected using an ultraviolet spectrophotometer (DU640, Beckman, USA), and a high purity indicated by an A260/A280 ratio was between 1.8 ~ 2.0. RNA was reversetranscribed to cDNA according to the instructions supplied with the Prime Script RT kit (Takara, Dalian, China). The reaction conditions were as follows: 37°C for 15 min and 85°C for 1 s, and the total volume of the reaction system was 20 μl. PCR was performed using a qRT-PCR instrument (ABI 7500, ABI, Foster City, CA, USA) with the SYBR Premix EX Taq kit (Takara, Dalian, Liaoning, China). The reaction systems consisted of 12.5 μl of SYBR Premix Ex TagII (2×), 0.5 μl of forward primer, 0.5 μl of reverse primer, 2 μl of cDNA and 9.5 μl of RNase Free dH 2 O. The reaction conditions were as follows: pre-denaturation at 95°C for 5 min, followed by 40 cycles of denaturation at 95°C for 5 s, and extension/annealing at 60°C for 30 s. Three repeated parallel wells were prepared for each sample. The primers for miR-34a, CXCL10, TLR2, TLR4, nuclear factor kappa B (NF-κB), vascular endothelial growth factor (VEGF), transforming growth factor beta1 (TGF-β1), U6 and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were synthetized by Shanghai Biotech Co., Ltd, and the sequences are shown in Table 1 . U6 was the internal reference for miR-34a, and GAPDH was the internal reference for the other target genes. The expression level of product was calculated by the 2 -ΔΔCt method (Ct, threshold cycle) with the following formula: ΔΔCt = (average Ct value of target genes in the case group -average Ct value of the house-keeping genes in the case group) -(average Ct value of target genes in the control group -average Ct value of the house-keeping genes in the control group). This method could also be applied to measure mRNA expression in cells.
Western blotting
A total of 50 mg of frozen breast cancer and normal tissues was added to liquid nitrogen, ground into a fine powder, supplemented with 500 μl of protein lysate (RIPA, Pierce, Rockford, IL, USA), incubated for 30 min on ice, and centrifuged at 12000 r/min at 4°C for 10 min. The supernatant from each sample was then collected, quantitatively assessed for protein content using colorimetry and diluted in deionized water to adjust the concentration. Then, 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was performed. Each well contained 120 μg of sample for electrophoresis at 80 V. When the samples entered the gel, electrophoresis was conducted at 120 V, and when the indicator reached the bottom of the gel, electrophoresis was stopped. After electrophoresis, the proteins were transferred onto a nitrocellulose (NC) membrane by the wet transfer method and mounted using Tris-buffered saline-Tween (TBST) buffer containing 5% dried skim milk for 60 min, followed by the addition of primary antibodies, namely, mouse anti-CXCL10 (1:50, ab8098), mouse anti-TLR2 (1:50, ab9100), rabbit anti-TLR4 (1:500, ab13556), rabbit anti-NF-κB (1:1000, ab32360), rabbit anti-VEGF (1:1000, ab32152), mouse anti-TGF-β1 (1:2000, ab27969) and mouse anti-GAPDH (1:500, ab8245) (all purchased from Abcam Ltd., Cambridge, UK), at 4°C overnight. The membrane was then washed three times with TBST for 7 min each. Next, horseradish Table 1 . Primer sequences for qRT-PCR. Note: qRT-PCR, quantitative real-time polymerase chain reaction; miR-34a, microRNA-34a; CXCL10, C-X-C motif chemokine 10; TLR2, toll-like receptor 2; TLR4, toll-like receptor 4; NF-κB, nuclear factor κB; VEGF, vascular endothelial growth factor; TGF-β1, transforming growth factor-β; GAPDH, glyceraldehyde-3-phosphate dehydrogenase
Genes
Primer sequences miR-34a 
Cell culture
Five common breast cancer cell lines, namely, MCF-7, MDA-MB-435, Bcap-37, T47D and BT-549 (Cell Bank of Chinese Academy of Sciences, Shanghai, China), were selected and cultured in Dulbecco's Modified Eagle's Medium (DMEM) (Gibco Company, Grand Island, NY, USA) with 10% fetal bovine serum (FBS, PAA Laboratories, Dartmouth, MA, USA) and 2 mmol/l glutamine (Sigma, St. Louis, MO, USA ) in a 5% CO 2 incubator (Thermo Fisher Scientific, Inc., Waltham, MA, USA) with saturated humidity at 37°C. When cell confluence reached 90%, cells were passaged. Briefly, the previous culture solution was discarded, the cells were washed twice with PBS, and 0.25% trypsin was applied for cell digestion at 37°C for 1 to 2 min. When intercellular space appeared, the trypsin was removed, and DMEM containing 10% FBS was applied to stop the digestion. A pipettor was then used to repeatedly pipette the cells to generate a single cell suspension. qRT-PCR was performed to measure miR-34a expression in 5 breast cancer cell lines, and the two lines with the highest expression were selected for the following experiments.
Cell grouping and transfection
Breast cancer cells were allocated into the following groups: blank (without any transfection), NC (transfected with nonsense sequence), miR-34a mimic (transfected with miR-34a mimic sequence), miR-34a inhibitor (transfected with miR-34a inhibitor sequence), siRNA-CXCL10 (transfected with siRNA-CXCL10-1, siRNA-CXCL10-2 and siRNA-CXCL10-3 sequences; the most effective silencing sequence was selected by qRT-PCR as the target plasmid) and OxPAPC (TLR signaling pathway inhibitor). The target plasmids were all purchased from Shanghai Genechem Co., Ltd. (Shanghai, China). Breast cancer cells were seeded in a 6-well plate (5 × 10 5 cells/well) and transfected at 80% confluence using Lipofectamine 2000 (Invitrogen, Carlsbad, CA). First, 4 μg of target plasmid and 10 μl of Lipofectamine 2000 were separately diluted in 250 μl of serum-free DMEM (Gibco, Grand Island, NY, USA) and gently mixed. After placing the mixtures at room temperature for 5 min, the two plasmids solutions were mixed together. After 20 min, the mixture was added to the cell culture wells, which were incubated in a 5% CO 2 incubator at 37°C. After 6 h of culture, the previous medium was replaced with complete medium, and the cells were incubated continuously in the 5% CO 2 incubator at 37°C for 48 h and then collected.
Dual-luciferase reporter assay
Target sequences of CXCL10-WT 3'UTR and CXCL10-MUT 3'UTR were constructed artificially, and a double enzyme digestion was performed with BamHI and XhoIII to insert the target fragment into the pmirGLO (Promega, Madison, WI, USA) reporter plasmid to obtain wild-type and mutant plasmids. After sequence verifications of the two reporter plasmids, they were co-transfected with the miR-34a mimic and NC into the MCF-7 and T47D cell lines. After transfection for 48 h, the cells were collected and split, and the Dual-Luciferase® Reporter Assay System (E1910, Promega, Madison, WI, USA) was used to measure luciferase activity. Each sample was supplemented with 100 μl of firefly luciferase reagent to measure firefly luciferase activity and 100 μl of renilla luciferase reagents to measure renilla luciferase activity; then, the relative luciferase activity was calculated. This experiment was repeated three times.
Cell counting kit-8 (CCK-8) assay
Cells in the logarithmic phase were selected from the six transfected groups, washed twice with PBS, added with 0.25% trypsin and centrifuged at 1000 rpm for 5 min. A pipettor was used to pipette the cells to generate a single cell suspension. A cell counting instrument was used to count the number of cells. Then, the cells were cultured in a 96-well plate (100 μl, 3 × 10 3 cell/well) in a 5% CO 2 incubator at 37°C. After culturing for 24 h, CCK-8 (Beyotime Institute of Biotechnology, Shanghai, China) (10 μl/well) solution was added, and the cells were further cultured in a 5% CO 2 incubator at 37°C for 2 h. The optical density (OD) Three parallel wells were prepared in each group to determine the mean value. The cell growth curve was drawn with the OD value on the Y-axis and time on the X-axis to measure cell proliferation.
Soft agar colony formation assay
Cells in the logarithmic phase were selected from the six transfected groups, treated with 0.25% trypsin, and mixed with a pipettor to generate a single cell suspension. After centrifugation, the cell concentration was adjusted to 2 × 10 4 cells/ml in DMEM with 10% FBS. Ultrapure water was applied to prepare 1.0% and 0.7% low-melting point agarose. A proportion of 1:1 1.0% agarose and 2× DMEM (with 10% FBS) was mixed at 40°C, and 1.5 ml of the mixture was seeded into a 6-cm culture dish to make matrigel after cooling and solidifying. A proportion of 1:1 0.7% agarose and 2× DMEM was mixed at 40°C and then combined with a 0.2 ml cell suspension. The mixtures were seeded into a culture dish covered with matrigel and cultured in a 5% CO 2 incubator at 37°C for 3 weeks after solidifying. Then, 0.5 ml of crystal violet staining solution was added for 1 h, followed by washing with PBS. An inverted microscope (IX-50, Olympus, Tokyo, Japan) was used to calculate the number of colonies containing > 50 cells.
Scratch test
A marker was used to evenly mark the back of the 6-well culture plate. Breast cancer cells in the logarithmic phase from the 6 groups were inoculated into a 6-well plate (2 × 10 5 cells/well). After 24 h of culture, the cells covered the whole plate, and scratches were created perpendicular to the mark on the culture plate using a 10-μl pipettor. PBS was used to wash away detached cells, followed by the addition of serum-free DMEM. Cells were incubated in an incubator with 5% CO 2 at 37°C, and samples were selected at 0 h and 48 h and photographed using an inverted microscope. Three parallel wells were prepared for each group. The cell migration ability in each group was determined based on the number of cells that traversed the scratch.
Transwell assay
Six groups of breast cancer cells in the logarithmic phase were digested with trypsin, washed once with PBS, and re-suspended in serum-free DMEM. After counting, the cell density was adjusted to 1 × 10 5 cells/ml. A total of 200 μl of cell suspension was added to the upper chamber of the Transwell plate (Millipore, Bedford, Mass., USA) covered with matrigel, and 0.5 ml of DMEM with 15% FBS was added to the bottom chamber of the Transwell plate. The cells were then cultured in an incubator with 5% CO 2 at 37°C for 48 h, fixed with 95% ethanol for 10 min, stained with 0.1% crystal violet for 10 min and washed with PBS to remove the unbound stain. After observation under an inverted microscope, the mean value was determined for 5 fields of cells that were randomly chosen from each chamber. This experiment was repeated three times. The cell invasion ability in each group was represented by the number of cells that traversed the matrigel.
Flow cytometry
Cells in the logarithmic phase were selected from the six transfected groups and digested with 0.25% trypsin. After the cell concentration was adjusted to 1 × 10 6 cells/ml, the cells were seeded in a 6-well plate for 48 h and washed twice with PBS to collect single cell suspensions. After centrifugation at 1000 r·min -1 for 5 min, the supernatant was removed. Cells were fixed with 700 ml/l ice-cold ethanol overnight and centrifuged at 1000 r·min -1 for 5 min, followed by removal of the supernatant and two washes with PBS. The cells were incubated with 1 mg/ml RNase, reacted at 37°C for 2 h and incubated on ice for 30 min with 100 mg/l propidium iodide solution (PI, Caltag, Burlingame, CA, USA). A flow cytometer (BD Biosciences, Franklin Lakes, NJ, USA) was used to measure the distribution of cells in the cell cycle at an excitation wavelength of 488 nm. For the apoptosis analysis, pre-chilled PBS was used to wash the cells twice, followed by centrifugation at 1000 r·min -1 for 5 min and removal of the supernatant. The cells were re-suspended in staining buffer at 1 × 10 6 cells/ml, followed by centrifugation at 1000 r·min -1 for 5 min and supernatant removal. The combined buffer of 100 mg/l Annexin V-FITC (Caltag) and 50 mg/l PI solution was added to each sample, followed by mixing, incubation in the dark for 30 min, and the addition of 200 μl of staining buffer. Flow cytometry was used to evaluate apoptosis at an excitation wavelength of 488 nm. This experiment was repeated three times to obtain the mean value. 
Statistical methods
Statistical analyses were conducted using SPSS 21.0 software (IBM Corp, Armonk, NY, USA). Each experiment was carried out three times. Measurement data are expressed as the mean ± standard deviation. Comparisons between two groups were performed using the t test, and comparisons among multiple groups were conducted by one-factor analysis of variance (ANOVA). Count data are expressed as a ratio or percentage after analysis by the chi-square test. P < 0.05 indicated statistical significance.
Results
Identification of target genes
To identify up-regulated genes in breast cancer, we screened breast cancer mRNA microarray datasets from GEO. By analysis of up-regulated genes in the gene expression profiles of mRNA microarray datasets GSE26910 and GSE33447, we found that CXCL10 was the most significantly upregulated gene in these 2 breast cancer profiles, as shown in Fig. 1 and 2 . Therefore, CXCL10 was selected as the target gene for this study.
Additionally, high CXCL10 expression was detected both in ductal and lobular carcinoma of the breast in the breast cancer profile GSE5764 (Fig. 2) .
GO enrichment analysis of DEGs
Next, we performed GO enrichment analysis of intersected gene expression profiles in GSE26910 and GSE33447 and found that CXCL10 mainly participated in the establishment of extracellular space; the protein product of the CXCL10 gene is mainly involved in cytokine receptor binding, CXCR3 chemokine receptor binding, cAMPdependent protein kinase regulator activity and protein kinase regulator activity. Analysis of the biological processes illustrated that the CXCL10 gene mainly participates in the cytokine-mediated signaling pathway, cellular response to cytokine stimulus and response to cytokines (Tables 2~4).
KEGG signaling pathway enrichment analysis of DEGs
We further conducted KEGG pathway enrichment analysis of intersected DEGs in GSE26910 and GSE33447 and found that CXCL10 was mainly implicated in the influenza A-related pathway, cytokine-cytokine receptor interactions, the TLR signaling pathway and the IL-17 signaling pathway ( Table 5 ). As shown in Fig. 3 , the TLR signaling pathway had the greatest potential to 
be associated with the generation and development of breast cancer, and CXCL10 was related to the TLR signaling pathway. Fig. 4 illustrates that CXCL10 could participate in cell invasion and migration by activating the TLR signaling pathway. Therefore, CXCL10 could participate in the invasion and migration of breast cancer cells by regulating the TLR signaling pathway.
miR-34a, as a down-regulated miR in breast cancer, is presumed to bind to the 3'UTR of CXCL10
A target prediction program (miRanda, http://www.microrna. org) was used to identify miRNAs targeting CXCL10. We identified the binding sites of miR-34a and CXCL10 (Fig. 5A) , as well as 16 miRs that might target CXCL10 (Fig. 5B) . Additionally, the breast cancer miR profile GSE38167 revealed that among miRs, miR-34a was the most significantly d o w n -r e g u l a t e d (Fig. 6) ; a network meta-analysis further illustrated that miR-34a is down-regulated in breast cancer (Fig. 7) .
Distinct pathohistological features are present in cancerous tissues in patients with breast cancer
Normal breast tissues have a neater structure without obvious interstitial fibrous proliferation and heteromorphism, a regular nucleus, even chromatin, normal cytoplasm, an obscure nucleolus and a small amount of inflammatory cell infiltration in the mesenchyme. In contrast, breast cancer tissues display Table 5 . KEGG pathway enrichment analysis of DEGs in the GSE26910 and GSE33447 breast cancer expression profiles. Note: KEGG, Kyoto Encyclopedia of Genes and Genomes; DEGs, differentially expressed genes; IBD, inflammatory bowel disease; IL-17, interleukin-17; Th17, T helper 17; CXCL10, C-X-C motif chemokine 10; RSAD2, radical S-adenosyl methionine domain containing 2; STAT1, signal transducer and activator of transcription 1; IL21R, interleukin 21 receptor; INHBA, ovine beta A-inhibin BGN, biglycan; MMP13, matrix metalloproteinase 13 Encyclopedia of Genes and G e n o m e s ; X-a x i s : -logP value; Y-axis: signaling pathway. The color gradation for the P value is shown on the right, and red denotes a close correlation. (Fig. 8) .
CXCL10 is positively expressed in cancerous tissues from patients with breast cancer CXCL10 protein was mainly expressed in the cytoplasm, exhibiting a diffuse distribution that stained yellow. The rate of positive expression of CXCL10 protein in normal breast tissue was clearly lower than that in breast cancer tissue (P < 0.05) (Fig.  9 ).
Among patients with breast cancer, miR-34a is down-regulated, CXCL10 is up-regulated, and the TLR signaling pathway is activated
As shown in Fig. 10 , compared with normal breast tissue, breast cancer tissue showed marked down-regulation of miR-34a expression, while the mRNA and protein expression levels of CXCL10, TLR2, TLR4, NF-ΚB, VEGF and TGF-β1 were clearly up-regulated (all P < 0.05). These findings indicate that the TLR signaling pathway is abnormally activated in breast cancer tissues. 
Low expression of miR34a and high expression of CXCL10 may be related to breast cancer progression
As illustrated in Table 6 , the rate of positive CXCL10 protein expression was unrelated to patient age, menstrual condition, tumor size, histological grade, LNM, TNM stage or expression of human epidermal growth factor receptor-2 (HER-2) and estrogen receptor (ER) (P > 0.05), but it was related to the expression of progesterone receptor (PR) (P < 0.05); the relative expression of miR-34a was unrelated to patient age, menstrual condition, tumor size, LNM, TNM stage, HER-2, ER or PR (P > 0.05), but it was related to the tumor histological grade (P < 0.05).
Use of MCF-7 and T47D
cell lines for in vitro experiments miR-34a expression was detected in the breast cancer cell lines MCF-7, MDA-MB-435, Bcap-37, T47D and BT-549 (Fig. 11) ; miR-34a expression was reduced in MDA-MB-435, Bcap-37 and BT-549 cells compared with MCF-7 and T47D cells. Therefore, the MCF-7 and T47D cell lines were chosen for subsequent experiments.
siRNA against CXCL10 effectively suppresses endogenous CXCL10 expression As shown in Fig. 12 , compared with the NC group, the siRNA-CXCL10-1, siRNA-CXCL10-2 and siRNA-CXCL10-3 groups showed down-regulation of CXCL10 mRNA to different extents at 48 h after transfection in the MCF-7 and T47D cell lines (all P < 0.05). The lowest CXCL10 expression was observed in the siRNA-CXCL10-1 group, which indicated that siRNA-CXCL10-1 had the highest silencing efficiency.
CXCL10 is a target of miR-34a
As shown in Fig. 13 , compared with the NC group, the wild-type miR-34a mimic group showed a marked decrease in luciferase activity (P < 0.05). Luciferase activity in the mutant plasmid group showed no obvious changes (P > 0.05). The results obtained for the MCF-7 Fig. 10 . The expression of miR-34a, CXCL10, TLR signaling pathwayrelated genes and tumor metastasis-related factors in breast cancer and normal breast tissuesNote: MiR-34a, microRNA-34a; TLR, toll-like receptor; NF-ΚB, nuclear factor kappa B; VEGF, vascular endothelial growth factor; TGF-β1, transforming growth factor beta1; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; CXCL10, C-X-C motif ligand 10. A, mRNA expression in normal breast tissues. B, Western blotting patterns in the tissues. C, Protein expression in the tissues. *, P<0.05 compared with the normal group.
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Figure 10
The expression of miR-34a, CXCL10, TLR signaling pathway-related genes and tumor metastasis-related factors in breast cancer and normal breast tissues Note: MiR-34a, microRNA-34a; TLR, toll-like receptor; NF-ΚB, nuclear factor kappa B; VEGF, vascular endothelial growth factor; TGF-β1, transforming growth factor beta1; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; CXCL10, C-X-C motif ligand 10. A, mRNA expression in normal breast tissues. B, Western blotting patterns in the tissues. C, Protein expression in the tissues. *, P < 0.05 compared with the normal group.
Cellular Physiology and Biochemistry
Cellular Physiology and Biochemistry cell line were in accordance with those for the T47D cell line, which indicated that miR-34a could target CXCL10 and down-regulate CXCL10 expression.
miR-34a suppresses functional CXCL10 and inhibits the TLR signaling pathway in breast cancer cells
As shown in Fig. 14 , the MCF-7 and T47D cell lines showed the same trend. Compared with the blank group, the NC group showed no differences in the expression levels of miR34a, CXCL10, TLR2, TLR4, NF-ΚB, VEGF and TGF-β1 (P > 0.05). Compared with the blank and NC groups, the miR-34a mimic and OxPAPC groups showed increased miR-34 expression, while the miR-34a mimic, siRNA-CXCL10 and OxPAPC groups displayed markedly decreased expression of CXCL10, TLR2, TLR4, NF-ΚB, VEGF and TGF-β1 (P < 0.05); the miR-34a inhibitor group demonstrated an obvious down-regulation of miR-34 expression but a dramatic up-regulation of the expression of CXCL10, TLR2, TLR4, NF-ΚB, VEGF and TGF-β1 
Cellular Physiology and Biochemistry
Cellular Physiology and Biochemistry (P < 0.05). The expression of miR-34a was not significantly different in the siRNA-CXCL10 group (P > 0.05). These findings illustrate that miR-34a can suppress the activation of the TLR signaling pathway and down-regulate the expression of NF-ΚB, VEGF and TGF-β1 by negative regulation of CXCL10.
miRNA-34a inhibition of the TLR signaling pathway via CXCL10 inhibits breast cancer cell survival As illustrated in Fig. 15 , cell proliferation trends in the MCF-7 and T47D cell lines were identical. Differences in cell proliferation in the blank and NC groups were not statistically significant (P > 0.05). Compared with the blank and NC groups, the miR-34a mimic, siRNA-CXCL10 and OxPAPC groups showed a clear decline in cell viability, while the miR-34a inhibitor group showed increased cell viability (all P < 0.05). These findings indicate that miR-34a can suppress breast cancer cell proliferation by negative regulation of CXCL10 expression. 14. The expression levels of miR-34a, CXCL10, TLR s i g n a l i n g pathway-related genes and tumor metastasisrelated factors in each transfected cell group Note: MiR34a, microR-NA-34a; TLR, Toll-like receptor; NF-ΚB, nuclear factor kappa B; VEGF, vascular endothelial growth factor; TGF-β1, transforming growth factor beta1; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; NC, negative control; CXCL10, C-X-C motif ligand 10. A and D, mRNA expression. B and E, Western blotting patterns. C and F, Protein expression. *, P<0.05 compared with the blank and NC groups. 
miRNA-34a inhibition of the TLR signaling pathway via CXCL10 inhibits anchorage-independent growth of breast cancer cells
The MCF-7 and T47D cell lines showed identical trends in anchorage-independent growth. The numbers of colonies in the blank and NC groups were not significantly different (P > 0.05). Compared with the blank and NC group, the miR-34a mimic, siRNA-CXCL10 and OxPAPC groups showed an obvious decline in colony number, while the miR-34a inhibitor group showed an increase (all P < 0.05) (Fig. 16) . These results suggest that miR-34a can inhibit the anchorage-independent growth of breast cancer cells by negative regulation of CXCL10 expression.
miRNA-34a inhibition of the TLR signaling pathway via CXCL10 suppresses breast cancer cell migration and invasion As illustrated in Fig. 17 , the cell migration and invasion trends for corresponding groups of MCF-7 and T47D cells were identical. Differences in cell migration and invasion in the blank and NC groups were not statistically significant (P > 0.05). Compared with the blank and NC groups, the miR-34a mimic, siRNA-CXCL10 and OxPAPC groups showed a clear down-regulation of cell migration and invasion ability, while the miR-34a inhibitor group showed an up-regulation of these events (all P < 0.05). Thus, miR-34a can suppress the migration and invasion of breast cancer cells by negative regulation of CXCL10 expression.
miRNA-34a inhibition of the TLR signaling pathway via CXCL10 blocks breast cancer cell cycle entry while inducing apoptosis
As shown by the flow cytometry results (Fig. 18 and Fig. 19 ), the MCF-7 and T47D cell lines showed identical cell cycle distribution and apoptosis rate trends. Differences in the cell cycle distribution and apoptosis rate in the blank and NC groups were not statistically significant (P > 0.05). Compared with the blank and NC groups, the miR-34a mimic, siRNA-CXCL10 and OxPAPC groups exhibited increased proportions of cells in G0/G1 phase but decreased proportions of cells in S phase and an increased apoptosis rate; opposite trends were obtained for the miR-34a inhibitor group (all P < 0.05). The above results indicate that miR-34a can promote the apoptosis of breast cancer cells by negative regulation of CXCL10 expression.
Discussion
Patients with breast cancer usually die of cancer recurrence even after adjuvant therapies and radical surgery [24] . In this study, we explored the effect of miR-34a on the invasion and migration of breast cancer cells by targeting CXCL10 through the TLR signaling pathway. We found that up-regulation of miR-34a expression suppressed breast cancer cell invasion and migration by targeting CXCL10 through inhibition of TLR signaling pathway activation. First, breast cancer tissues showed suppressed miR-34a expression and promoted mRNA and protein expression of CXCL10, TLR2, TLR4, NF-ΚB, VEGF and TGF-β1. The expression of miR-34a, which is elevated in normal tissues, is inhibited in a variety of malignancies, including breast cancer [25, 26] . Li et al. reported the down-regulation of miR-34a in breast cancer [27] . Elevated CXCL10 expression in breast cancer has been validated by Ejaeidi et 
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Cellular Physiology and Biochemistry al [28] .. Additionally, TLR4 VEGF, TGF-β1 and NF-κB have been confirmed to be activated in breast cancer [29, 30] . Therefore, in breast cancer, miR-34 is down-regulated, and CXCL10 expression and the TLR signaling pathway are activated. Second, transfected cells in the miR-34a mimic group displayed increased miR-34a expression and decreased mRNA and protein expression of CXCL10, TLR2, TLR4, NF-ΚB, VEGF and TGF-β1; opposite trends were observed in the miR-34a inhibitor group. CXCL10 has also been claimed to be a chemokine that is negatively influenced by miR-21 [31] . A previous study illustrated a reverse relationship between the expression levels of miR-34a and the chemokine CCL22 [32] . Additionally, CXCL10 has been verified to be negatively regulated by miR-155 in human mesangial cells [33] . miR-34a regulates its target gene expression by binding to the 3'-UTR of its target mRNA [34] . Aomatsu et al. reported that CXCL10 expression in colonic myofibroblasts is suppressed by tacrolimus and that overexpression of miR-34a represses its target gene CD44 in osteosarcoma cells [35, 36] . The down-regulation of CXCL10 might be caused by c-Fos, a prominent member of the AP-1 family, when mediated by TNF-related apoptosis-inducing ligand [37] . Therefore, the present results indicated that miR-34a negatively regulated CXCL10 expression. miR-34a, as a tumor suppressor, targets a variety of cardinal oncogenic pathways [25] . One study reported that miR-34a negatively activates the epidermal growth factor receptor signaling pathway in gastric carcinoma [38] . The close relationship between VEGF and TLR2 has previously been verified by Gao et al., who claim that inhibiting TLR2 and TLR4 activity decreases VEGF expression [39] . Furthermore, miR-34a also negatively regulates VEGF in colorectal cancer by stimulating the non-receptor cytoplasmic tyrosine kinase focal adhesion kinase at Y397 [40] . In the presence of thyroid hormone T3 overexpression, miR-34a inhibits TGF-β1 expression via nucleotide base pairing between the 3'-untranslated region of the target mRNA and the complementary sequence of miRs [41] . Moreover, miR-146a has also been shown to negatively regulate TLR2 signaling, VEGF and NF-kB by inhibiting the Wnt/β-catenin pathway via the suppression of nuclear β-catenin accumulation [42, 43] . In hepatocellular cancer, decreased mRNA expression of miR-34a and protein expression of TLR4 were shown by modification of the binding of hasmiR-34a by rs1057317 to TCR4 [44] . The results implied that miR-34a inactivated the TLR signaling pathway by negatively regulating CXCL10.
Finally, cells transfected with the miR-34a mimic showed increased migration and invasion, with opposite trends obtained in the miR-34a inhibitor group. Overexpression of miR-34a has been confirmed to reduce apoptosis and inhibit cancer regeneration, migration and invasion [45] . Transcriptional activation of miR-34a has been reported to induce p53 (an effective tumor suppressor)-meditated apoptosis [46] . Li et al. reported that miR-34a suppresses breast cancer cell proliferation and invasion and induces apoptosis, consistent with the results of the present study [27] . By negatively regulating the translation and stability of its multiple target mRNAs, miR-34a has important effects on the cell cycle, migration, proliferation and invasion [45, 47] . These findings demonstrate that miR-34a oppresses cell migration and invasion in breast cancer.
Collectively, the key finding of the present study is that overexpression of miR-34a inhibits the migration and invasion of breast cancer cells by targeting CXCL10 via suppression of the TLR signaling pathway.
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